The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Ecabetum     (1R,4aS,10aR)-1,4a-dimethyl- 7-propan-2-yl...

Synonyms: Gastrom, Ecabet, Ecabet (INN), Ecabet [INN], CHEMBL2104585, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ecabet


High impact information on Ecabet


Chemical compound and disease context of Ecabet


Biological context of Ecabet


Anatomical context of Ecabet

  • Ecabet prevented both the pepsin-induced molecular size shift in mucus glycoproteins, and morphological alteration of the epithelium, including ultrastructural derangement of the mucus gel layer [15].
  • However, there is little understanding of how ecabet induces anti-inflammatory activity in gastric epithelial cells infected with H. pylori [11].
  • Ecabet sodium significantly inhibited pepsin activity in human gastric juice, with a maximum inhibition of 78% [4].
  • The aim of this study was to examine the effects of ecabet sodium on ROS produced by human neutrophils, particularly after being primed by bacterial lipopolysaccharides (LPS) [16].
  • To define the mechanism of the protection by ecabet sodium of the gastric mucosa, the characteristics of protein binding of this drug were investigated using a quartz-crystal microbalance (QCM) method [13].

Associations of Ecabet with other chemical compounds


Gene context of Ecabet


Analytical, diagnostic and therapeutic context of Ecabet


  1. Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis. Iizuka, M., Itou, H., Konno, S., Shirasaka, T., Horie, Y., Shindo, K., Watanabe, S. Gut (2006) [Pubmed]
  2. Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Shibata, K., Ito, Y., Hongo, A., Yasoshima, A., Endo, T., Ohashi, M. Antimicrob. Agents Chemother. (1995) [Pubmed]
  3. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Kono, T., Nomura, M., Kasai, S., Kohgo, Y. Am. J. Gastroenterol. (2001) [Pubmed]
  4. Mucosal protective effects of ecabet sodium: pepsin inhibition and interaction with mucus. Pearson, J.P., Roberts, N.B. Clin. Sci. (2001) [Pubmed]
  5. Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial. Lee, J.H., Kim, J.J., Hahm, K.B., Lee, D.H., Kim, N., Kim, S.K., Park, J.J., Choi, S.R., Lee, J.H., Lee, S.T., Lee, E.H., Rhee, J.C. World J. Gastroenterol. (2006) [Pubmed]
  6. Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells. Kusumoto, K., Kawahara, T., Kuwano, Y., Teshima-Kondo, S., Morita, K., Kishi, K., Rokutan, K. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) [Pubmed]
  7. High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Kagaya, H., Kato, M., Komatsu, Y., Mizushima, T., Sukegawa, M., Nishikawa, K., Hokari, K., Takeda, H., Sugiyama, T., Asaka, M. Aliment. Pharmacol. Ther. (2000) [Pubmed]
  8. Therapeutic effects of ecabet sodium, an antiulcer drug, on dextran sodium sulfate-induced ulcerative colitis in rats. Noto, T., Yamada, H., Inui, T., Okuyama, K., Watanable, A., Kimura, I., Nagasaki, M. Dig. Dis. Sci. (2005) [Pubmed]
  9. Protective effects of an antiulcer agent, ecabet sodium on colorectal carcinogenesis in rodents. Yarimizu, T., Mitamura, T., Suzuki, S., Sakamoto, S. Oncol. Rep. (1998) [Pubmed]
  10. Role of pancreatic trypsin in chronic esophagitis induced by gastroduodenal reflux in rats. Naito, Y., Uchiyama, K., Kuroda, M., Takagi, T., Kokura, S., Yoshida, N., Ichikawa, H., Yoshikawa, T. J. Gastroenterol. (2006) [Pubmed]
  11. Inhibition of Helicobacter pylori-induced nuclear factor-kappa B activation and interleukin-8 gene expression by ecabet sodium in gastric epithelial cells. Kim, J.M., Kim, J.S., Jung, H.C., Oh, Y.K., Kim, N., Song, I.S. Helicobacter (2003) [Pubmed]
  12. Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein. Ito, Y., Onoda, Y., Nakamura, S., Tagawa, K., Fukushima, T., Sugawara, Y., Takaiti, O. Jpn. J. Pharmacol. (1993) [Pubmed]
  13. A kinetic study of protein binding to ecabet sodium using quartz-crystal microbalance. Kawakami, K., Yasuda, M., Ishii, K., Kokusenya, Y., Sato, T. Chem. Pharm. Bull. (1999) [Pubmed]
  14. Possible mechanism of increase in gastric mucosal PGE2 and PGI2 generation induced by ecabet sodium, a novel gastroprotective agent. Kinoshita, M., Tamaki, H. Dig. Dis. Sci. (1997) [Pubmed]
  15. Ecabet sodium, a novel locally-acting anti-ulcer agent, protects the integrity of the gastric mucosal gel layer from pepsin-induced disruption in the rat. Kinoshita, M., Endo, M., Yasoshima, A., Saito, N., Yamasaki, K., Chishima, S., Narita, H. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  16. Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Munakata, W., Liu, Q., Shimoyama, T., Sawaya, M., Umeda, T., Sugawara, K. Luminescence : the journal of biological and chemical luminescence. (2003) [Pubmed]
  17. Relationship between gastroprotective effect of locally acting antiulcer agent ecabet sodium and its binding to gastric mucosa in rats. Comparison with sucralfate. Kinoshita, M., Yamasaki, K., Kokusenya, Y., Tamaki, H. Dig. Dis. Sci. (1995) [Pubmed]
  18. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Nagahama, K., Yamato, M., Nishio, H., Takeuchi, K. Dig. Dis. Sci. (2006) [Pubmed]
  19. Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa. Ichikawa, T., Ishihara, K., Hayashida, H., Hiruma, H., Saigenji, K., Hotta, K. Dig. Dis. Sci. (2000) [Pubmed]
  20. Effects of ecabet sodium on experimentally induced reflux esophagitis. Omura, N., Kashiwagi, H., Chen, G., Yano, F., Suzuki, Y., Aoki, T. J. Gastroenterol. (2000) [Pubmed]
  21. Effect of a combination of ecabet sodium and cimetidine on experimentally induced gastric lesions and gastric mucosal resistance to ulcerogenic agents in rats. Kinoshita, M., Noto, T., Tamaki, H. Biol. Pharm. Bull. (1995) [Pubmed]
WikiGenes - Universities